MX2010004671A - Seprasa como marcador para cancer. - Google Patents

Seprasa como marcador para cancer.

Info

Publication number
MX2010004671A
MX2010004671A MX2010004671A MX2010004671A MX2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A MX 2010004671 A MX2010004671 A MX 2010004671A
Authority
MX
Mexico
Prior art keywords
cancer
seprase
types
lung
evaluation
Prior art date
Application number
MX2010004671A
Other languages
English (en)
Spanish (es)
Inventor
Michael Tacke
Johann Karl
Markus Roessler
Wolfgang Rollinger
Jarema Peter Kochan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010004671A publication Critical patent/MX2010004671A/es

Links

Classifications

    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G01N33/57535—
    • G01N33/57557—
    • G01N33/57565—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2010004671A 2007-12-10 2008-12-08 Seprasa como marcador para cancer. MX2010004671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
MX2010004671A true MX2010004671A (es) 2010-05-27

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004671A MX2010004671A (es) 2007-12-10 2008-12-08 Seprasa como marcador para cancer.

Country Status (14)

Country Link
US (1) US8980573B2 (enExample)
EP (1) EP2223115B1 (enExample)
JP (1) JP5563988B2 (enExample)
KR (1) KR101202220B1 (enExample)
CN (1) CN101896818B (enExample)
AT (1) ATE524740T1 (enExample)
AU (1) AU2008335855B2 (enExample)
BR (1) BRPI0820793A2 (enExample)
CA (1) CA2706115A1 (enExample)
DK (1) DK2223115T3 (enExample)
ES (1) ES2372442T3 (enExample)
MX (1) MX2010004671A (enExample)
PL (1) PL2223115T3 (enExample)
WO (1) WO2009074275A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
ES2408964T3 (es) * 2008-07-03 2013-06-24 F. Hoffmann-La Roche Ag ASC como marcador del cáncer de pulmón
NZ600828A (en) 2009-12-20 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2585184T3 (es) * 2010-02-05 2016-10-04 Astute Medical, Inc. Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20130225442A1 (en) * 2010-10-20 2013-08-29 Rush University Medical Center Lung Cancer Tests
CA2826820A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
CN103415772A (zh) * 2011-03-11 2013-11-27 霍夫曼-拉罗奇有限公司 表面表达蛋白酶作为慢性阻塞性肺病（copd）的标志物
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
US20140038838A1 (en) 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
SG11201504241QA (en) * 2012-11-30 2015-06-29 Applied Proteomics Inc Method for evaluation of presence of or risk of colon tumors
US9360488B2 (en) 2013-01-17 2016-06-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
EP3080299B1 (en) 2013-12-09 2020-09-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
CA2970143A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
JP7134502B2 (ja) * 2017-09-05 2022-09-12 オンコタグ ダイアグノスティクス シーオー．， エルティーディー． メチオニルｔＲＮＡ合成酵素を利用した膵臓癌の診断方法及びこれを利用した膵臓癌の診断キット
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
WO2005043121A2 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
BRPI0620027A2 (pt) * 2005-12-19 2011-10-25 Tufts College inibidores da protease soft e formas pró-soft

Also Published As

Publication number Publication date
EP2223115B1 (en) 2011-09-14
PL2223115T3 (pl) 2012-02-29
BRPI0820793A2 (pt) 2015-06-16
AU2008335855A1 (en) 2009-06-18
ATE524740T1 (de) 2011-09-15
ES2372442T3 (es) 2012-01-19
DK2223115T3 (da) 2011-12-12
US20100240081A1 (en) 2010-09-23
CN101896818A (zh) 2010-11-24
US8980573B2 (en) 2015-03-17
WO2009074275A1 (en) 2009-06-18
EP2223115A1 (en) 2010-09-01
KR101202220B1 (ko) 2012-11-16
CN101896818B (zh) 2016-01-20
JP2011506941A (ja) 2011-03-03
JP5563988B2 (ja) 2014-07-30
HK1150884A1 (zh) 2012-01-13
AU2008335855B2 (en) 2012-08-30
CA2706115A1 (en) 2009-06-18
KR20100091212A (ko) 2010-08-18

Similar Documents

Publication Publication Date Title
MX2010004671A (es) Seprasa como marcador para cancer.
WO2010072383A8 (en) Armet as a marker for cancer
ATE554389T1 (de) Apex als marker für lungenkrebs
ES2683362T3 (es) Microvesículas obtenidas a partir de células tumorales
AR077901A1 (es) Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
IL201778A0 (en) Peptide imaging agents
WO2011086174A3 (en) Diagnostic gene expression platform
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
NZ621733A (en) Lung cancer biomarkers and uses thereof
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
WO2014026768A8 (en) Colorectal cancer markers
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
EP2212700B8 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2009143181A3 (en) Micro-rna profile in human saliva and its use for detection of oral cancer
MX2012007940A (es) Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.
EP2576832A4 (en) COMPOSITIONS AND METHODS FOR DETECTING NEOPLASIA
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer
MX2016011453A (es) Sistemas y metodos de codificacion para la calibracion de biosensores.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom

Legal Events

Date Code Title Description
FG Grant or registration